ClinicalTrials.gg
RecruitingNCT06392477Updated Dec 23, 2025

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma

A Phase 1 interventional study of SAR448501 in B-cell Non Hodgkin Lymphoma, sponsored by Sanofi. Recruiting at 16 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 63 studies in Lymphoma, B-Cell with a site in Australia — 18 open to participants now, 38 under way, 14 of them phase 3. Lymphoma, B-Cell · Australia.

Planned enrollment
43rd of 63
96 · median 188
Started
2024
with 9 others
Phase 1
22 of 63
7 open now
Primary completion
2028-01
later than 17 of 37 live
Registered
50th of 63
by date

Among the 63 studies in Lymphoma, B-Cell with a site in Australia, this one is the 43rd largest by planned enrollment, is one of 10 that started in 2024, is one of 22 in phase 1, reaches primary completion later than 17 of the 37 other live ones, and was the 50th registered.

Lymphoma, B-Cell

886 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

18 of the 63 studies in Lymphoma, B-Cell with a site in Australia are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 208 Lymphoma, B-Cell studies recruiting now, 128 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Lymphoma, B-Cell with a site in Australia, or all of them as a file.
02

Study summary

This is an open-label, multiple ascending dose (MAD), phase 1 study in adult patients with relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL). The purpose of the study is to identify possible optimal biological dosage(s) by assessing safety, tolerability, pharmacokinetics (PK), pharmacodynamics, clinical activity and immunogenicity of SAR448501/DR-0201.

The study duration per participant will be approximately 3 years, including a screening period of up to 28 days, a treatment period of 52 weeks, a safety follow-up period of approximately 28 days and a long-term follow-up period of every 3 months until withdrawal of consent, participant death or study closure, whichever is sooner.

03

Conditions studied

  • B-cell Non Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with R/R B-NHL which has failed at least 2 prior lines available life-prolonging standard therapy and without treatment options that are recognized to offer clinical benefit.
  • Adequate marrow reserve, renal function, and hepatic function.
  • defined as ≥ 1 bi-dimensionally measurable nodal lesion of > 1.5 cm in the longest dimension for participants with fluorodeoxyglucose (FDG)-avid disease for subtypes with nodular disease or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension.
  • (ECOG) performance status 0-1.
  • of ≥ 12 weeks.
  • Use of a highly effective measure for all males and all females of during study through 180 days post last dose; Females of childbearing potential need to have a negative serum pregnancy test within 7 days prior to first dose.
  • Tumor tissue block or 3 to 5 unstained slides from lymph node or other relevant collected in the past 12 months. Participants must be willing to provide a baseline and at least 1 on-treatment biopsy, unless not safely accessible.
  • Participants who have received prior CAR-T therapy must be >60 days post CAR-T at day of first dosing.

Exclusion criteria

Exclusion Criteria:

  • Burkitt's or Burkitt's like lymphoma or lymphoplastic lymphoma.
  • Current history of central nervous system (CNS) involvement by .
  • Prior stem cell transplantation except for those with follicular lymphoma (FL) and mantle cell lymphoma (MCL), who are excluded if transplant occurred less than 100 days prior to dosing or if they exhibit grade > 1 .
  • Prior solid organ transplantation.
  • Autologous stem cell transplantation ≤ 100 days prior to dosing.
  • History of disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematous, rheumatoid arthritis, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjorgen's syndrome, Guillain-Barre-syndrome, multiple sclerosis vasculitis, or glomerulonephritis (participants with a remote history of, or well-controlled autoimmune disease, may be eligible).
  • Major surgery in the last 28 days prior to dosing.
  • Evidence of significant, uncontrolled concomitant disease that could affect compliance with study.
  • Current or past history of CNS disease (participants with remote history of non-lymphoma CNS disease and with no residual neurologic deficits may be eligible to enroll).
  • corrected by Fridericia's formula (QTcF) > 480 msec.
  • Significant cardiovascular disease.
  • Received any anticancer systemic therapy within 4 weeks prior to first drug administration or 5 half-lives of the drug, whatever is shorter. Treatment with ≤ 25 mg/day prednisone or equivalent is allowed. Inhaled and topical steroids are allowed.
  • Known infection with , virus (HBV) or virus (HCV).
  • Active infection at baseline requiring systemic treatment with antimicrobial, antifungal, or antiviral agents in the 2 weeks prior to dosing.
  • Administration of a live, attenuated vaccine within 4 weeks prior to first drug administration or anticipation that such vaccine administration would be necessary during the course of the study.
  • Another invasive malignancy in the last 2 years (except basal cell carcinoma or squamous cell carcinoma of the skin, asymptomatic prostate cancer requiring only hormonal therapy and with normal prostate-specific antigen for > 1 year, and tumors deemed by the investigator to be of low likelihood for recurrence).
  • /international normalized ratio (INR) and activated partial thromboplastin time or partial thromboplastin time (aPTT/PTT) > 1.3 × or outside the therapeutic range of the local laboratory if receiving therapeutic anticoagulation that would affect the prothrombin time/INR, participants with a history of a hypercoagulation event within 6 months, or participants who have known hypercoagulation risk factors will be excluded.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    SAR448501 dose escalation

    SAR448501 will be administered for up to 52 weeks. Different cohorts with up to 8 dose levels will be included.

    Drug: SAR448501

Interventions

  • Bispecific antibody

    Also known as: DR-0201

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse event (TEAE)

    Time frame: Baseline to 28 days post last dose

  2. Potential pharmacologically optimized dose/regimen(s) of SAR448501 / DR-0201 in participants with R/R B-NHL

    Potential pharmacologically optimized dose/regimen(s) of SAR448501/DR-0201 in participants with R/R B-NHL as determined using an integrated assessment of efficacy, safety, pharmacokinetic (PK)/pharmacodynamic (PD), and exposure-response relationships

    Time frame: Cycle 1 (Day 1 to Day 28)

Secondary outcomes

  1. Response rate assessed for CLL

    Response rate assessed for chronic lymphocytic leukemia (CLL) by International Workshop on Chronic Lymphocytic Leukemia (iwCLL). The iwCLL response is based on the overall physical examination and evaluation of blood and bone marrow: complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD).

    Time frame: Baseline until disease progression (up to the end of treatment at Week 52)

  2. Response rate assessed for all other B-NHL lymphomas

    Response rate assessed for all other B-NHL lymphomas by Lugano response criteria. The Lugano response is based on the overall radiographic response: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), not evaluable (NE) and not available (NA).

    Time frame: Baseline until disease progression (up to the end of treatment at Week 52)

  3. Duration of response/remission (DOR)

    DOR is defined as the time between first disease response and date of disease progression or death due to any cause, whichever occurs first.

    Time frame: Baseline until disease progression (up to the end of treatment at Week 52)

  4. Complete response/remission rate (CRR)

    Proportion of participants who have a complete response/remission, based on the disease assessments by the Investigator.

    Time frame: Baseline until the end of treatment (Week 52)

  5. Time to response (TTR in months)

    TRR is defined as the time between the first administration of investigational medicinal product (IMP) at Cycle 1 Day 1 (C1D1) until first documented disease response.

    Time frame: Baseline until the end of treatment (Week 52)

  6. Progression-free survival (PFS)

    PFS is defined as the time between the first administration of IMP at C1D1 and date of disease progression or death due to any case, whichever occurs first.

    Time frame: Baseline until disease progression (up to the end of treatment at Week 52)

  7. Overall survival (OS)

    OS is defined as the time between the first administration of IMP (C1D1) and death due to any cause.

    Time frame: Baseline until disease progression (up to the end of treatment at Week 52)

  8. Assessment of pharmacokinetic (PK) parameters: AUC0-t

    Area under the plasma concentration versus time curve calculated using the trapezoidal method during a dosing interval (t)

    Time frame: Baseline to 28 days post last dose

  9. Assessment of PK parameters: Cmax

    Maximum observed plasma concentration

    Time frame: Baseline to 28 days post last dose

  10. Assessment of PK parameters: Tmax

    Time to reach Cmax

    Time frame: Baseline to 28 days post last dose

  11. Assessment of PK parameters: terminal elimination half-life

    Time for the concentration to decrease in half

    Time frame: Baseline to 28 days post last dose

  12. Incidence of anti-drug antibodies (ADAs)

    Incidence of anti-drug antibodies (ADAs) against SAR448501/DR-0201

    Time frame: Baseline to 28 days post last dose

07

Study locations

15 of 16 sites recruiting
  • Investigational Site Number : 001-203
    Camperdown, New South Wales 2050, Australia
    Recruiting
  • Investigational Site Number : 001-202
    Townsville, Queensland 4814, Australia
    Recruiting
  • Investigational Site Number : 001-205
    Adelaide, South Australia 5000, Australia
    Recruiting
  • Investigational Site Number : 001-204
    Melbourne, Victoria 3121, Australia
    Recruiting
  • Investigational Site Number : 001-201
    Perth, Western Australia 6009, Australia
    Recruiting
  • Investigational Site Number : 001-703
    Kamenitz, 21204, Serbia
    Active, not recruiting

    Not enrolling at this site.

  • Investigational Site Number : 001-601
    Singapore, 119074, Singapore
    Recruiting
  • Investigational Site Number : 001-602
    Singapore, 308433, Singapore
    Recruiting
  • Investigational Site Number : 001-401
    Busan, 48108, South Korea
    Recruiting
  • Investigational Site Number : 001-403
    Busan, 49201, South Korea
    Recruiting
  • Investigational Site Number : 001-404
    Goyang-si, 10408, South Korea
    Recruiting
  • Investigational Site Number : 001-402
    Seoul, 03080, South Korea
    Recruiting
  • Investigational Site Number : 001-405
    Seoul, 06351, South Korea
    Recruiting
  • Investigational Site Number : 001-503
    Changhua, 505, Taiwan
    Recruiting
  • Investigational Site Number : 001-502
    Kaohsiung City, 83301, Taiwan
    Recruiting
  • Investigational Site Number : 001-501
    Taipei, 10048, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jan 2028, 42 months after the start.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 42 months is below that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
Apr 30, 2024
StartActual
Jul 8, 2024
Primary completionEst.
Jan 21, 2028
CompletionEst.
Feb 11, 2028
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06392477
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 30, 2024
Start date
Jul 8, 2024
Primary completion
Jan 21, 2028 (estimated)
Completion
Feb 11, 2028 (estimated)
Last update
Dec 23, 2025

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6
Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD20 Bispecific Antibody DR-0201

Start the discussion